AR119418A1 - Composiciones de pretomanid - Google Patents

Composiciones de pretomanid

Info

Publication number
AR119418A1
AR119418A1 ARP200101995A ARP200101995A AR119418A1 AR 119418 A1 AR119418 A1 AR 119418A1 AR P200101995 A ARP200101995 A AR P200101995A AR P200101995 A ARP200101995 A AR P200101995A AR 119418 A1 AR119418 A1 AR 119418A1
Authority
AR
Argentina
Prior art keywords
pretomanid
granulate
weight
compositions
composition
Prior art date
Application number
ARP200101995A
Other languages
English (en)
Inventor
Thomas Brad Gold
Graham Stanley Leonard
Rajneesh Taneja
Original Assignee
The Global Alliance For Tb Drug Dev Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Global Alliance For Tb Drug Dev Inc filed Critical The Global Alliance For Tb Drug Dev Inc
Publication of AR119418A1 publication Critical patent/AR119418A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describe una composición farmacéutica oral que incluye un granulado que incluye una cantidad farmacéuticamente efectiva de pretomanid o un solvato farmacéuticamente aceptable del mismo. Dicho granulado puede tener una densidad aparente en un rango de aproximadamente 0,3 a 0,8 g/mL y/o una distribución de tamaño de partícula de modo tal que no más de aproximadamente 30% en peso del granulado es retenido en un tamiz ASTM #60 (250 mm). En particular, se provee una composición en donde al menos el 40% en peso del pretomanid (por ejemplo, al menos el 60% en peso) es disuelto dentro de 20 minutos según se mide en un Aparato USP-II a 37 ± 2ºC en bromuro de hexadeciltrimetilamonio (HDTMA) al 0,5% en HCl 0,1N.
ARP200101995A 2019-07-19 2020-07-16 Composiciones de pretomanid AR119418A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962876257P 2019-07-19 2019-07-19

Publications (1)

Publication Number Publication Date
AR119418A1 true AR119418A1 (es) 2021-12-15

Family

ID=74192882

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200101995A AR119418A1 (es) 2019-07-19 2020-07-16 Composiciones de pretomanid

Country Status (9)

Country Link
EP (1) EP3999039A4 (es)
JP (2) JP7455189B2 (es)
KR (1) KR20210152506A (es)
AR (1) AR119418A1 (es)
AU (1) AU2020316989B2 (es)
BR (1) BR112022000899A2 (es)
CA (1) CA3143829A1 (es)
MX (1) MX2022000816A (es)
WO (1) WO2021016012A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021257461A1 (en) * 2020-06-15 2021-12-23 Mylan Laboratories Limited Combination antibacterial composition and method for antibacterial therapy
AU2022214530A1 (en) * 2021-02-01 2023-08-17 The Global Alliance For Tb Drug Development, Inc. Pretomanid amorphous form
EP4316463A1 (en) * 2022-08-02 2024-02-07 GlaxoSmithKline Intellectual Property Development Limited Novel formulation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1590144B1 (en) * 2002-12-10 2015-07-29 Nortec Development Associates, Inc. Method of preparing biologically active formulations
JP5258224B2 (ja) * 2006-08-08 2013-08-07 信越化学工業株式会社 固体分散体の固形製剤及びその製造方法
US7998505B2 (en) * 2006-10-27 2011-08-16 Fmc Corporation Dry granulation binders, products, and use thereof
AR065802A1 (es) * 2007-03-22 2009-07-01 Schering Corp Formulaciones de comprimidos que contienen sales de 8- [( 1- ( 3,5- bis- (trifluorometil) fenil) -etoxi ) - metil) -8- fenil -1, 7- diaza- spiro [ 4,5] decan -2- ona y comprimidos elaborados a partir de estas
US8298585B2 (en) * 2007-06-06 2012-10-30 Asahi Kasei Chemicals Corporation Cellulose-based fine core particle and process for producing the same
WO2015126922A2 (en) * 2014-02-18 2015-08-27 Stc. Unm Rapid phenotype tests for antitubercular drug sensitivity and resistance
CN108495631A (zh) * 2015-10-14 2018-09-04 结核病药物开发全球联盟公司 联合抗菌组合物以及短疗程抗菌方案
WO2017121340A1 (zh) * 2016-01-12 2017-07-20 广东东阳光药业有限公司 阿哌沙班固体组合物及其制备方法

Also Published As

Publication number Publication date
EP3999039A4 (en) 2023-06-07
WO2021016012A1 (en) 2021-01-28
BR112022000899A2 (pt) 2022-03-29
JP2022541583A (ja) 2022-09-26
EP3999039A1 (en) 2022-05-25
MX2022000816A (es) 2022-05-13
KR20210152506A (ko) 2021-12-15
JP2024042090A (ja) 2024-03-27
CA3143829A1 (en) 2021-01-28
AU2020316989B2 (en) 2024-02-15
AU2020316989A1 (en) 2022-03-03
JP7455189B2 (ja) 2024-03-25
WO2021016012A8 (en) 2021-02-25

Similar Documents

Publication Publication Date Title
AR119418A1 (es) Composiciones de pretomanid
CY1119357T1 (el) Φαρμακευτικες συνθεσεις που περιλαμβανουν συνδετες υποδοχεων σιγμα
CY1117434T1 (el) Φαρμακευτικες μορφες απιξαμπανης
BRPI0705488A (pt) composição nanoparticulada estável, métodos de preparar a mesma e de prevenir e/ou tratar uma infecção bacteriana, composição farmacêutica, e, forma de dosagem
CU20100200A7 (es) Una composición farmacéutica que comprende n-(3,4-difluoro-2-4-iodofenilamino)-6-metoxifenil)-l-(2,3-dihidroxipropil)ciclopropano-l-sulfonamida, útil para el tratamiento y prevención del cáncer y de enfermedades inflamatorias
AR054347A1 (es) Combinaciones terapeuticas para el tratamiento o la prevencion de la depresion
BRPI0508461B8 (pt) diaminopirimidinas, seus usos, e composição farmacêutica
CL2008003431A1 (es) Compuestos derivados de nucleosidos 2',4' sustituidos; proceso de preparacion de dichos compuestos; composicion farmaceutica que los comprende; su metodo de preparacion; y su uso para el tratamiento y/o la prevencion de cualquier condicion resultante de una infeccion por vhb, vhc o vih.
NO20075042L (no) Farmasoytisk sammensetning innbefattende en omega-karboksyarylsubstituert difenylurea for behandling av cancer
AR054064A1 (es) Composicio con ingrediente farmaceutico activo en base a canabinoide para formas de dosis mejoradas
MX2021010106A (es) Inhibidores de la via de respuesta al estres integrada.
CO2021017031A2 (es) Derivados de aminoquinazolina como inhibidores del purinoreceptor 3 de p2x (p2x3)
CO6290670A2 (es) Derivados de pirimidina utiles para el tratamiento de condiciones inflamatorias o alergicas
CL2004000590A1 (es) Compuestos derivados de 1,3,4-oxadiazol-3-ona, 1,3,4-tiadiazol-2-ona y de 1,2,4-triazol-3-ona; composicion farmaceutica que los contiene; procedimiento de preparacion y su uso en la preparacion de un medicamento en los que esta relacionado el virus v
RU2007137846A (ru) Инъецируемые препаративные формы депо и способы обеспечения замедленного высвобождения композиций, состоящих из наночастиц
ZA200700827B (en) Anti-inflammatory agents
MX2020002769A (es) Composiciones de polvo seco con estearato de magnesio.
IL276194B2 (en) Pharmaceutical compounds or preparations containing them for use in the treatment of pain
DE60313296D1 (de) Pharmazeutische darreichungsformen, welche einen tablettenkern mit einer bruchfestigkeit unter 38n/qcm und einen überzug zum schutz des weichen kerns enthalten
CO6640318A2 (es) Formas de dosificación oral de bendamustina
CO2024000054A2 (es) Forma cristalina de tolebrutinib y método de preparación y su uso
BR112012022209A2 (pt) composições farmacêuticas compreendendo monoterpenos
MX2021006012A (es) Derivados de amino triazolo quinazolina 7-, 8-, y 10-sustituidos como antagonistas de receptor de adenosina, composiciones farmaceuticas y su uso.
BRPI0410623A (pt) composto, processo para preparação de um composto, composição farmacêutica, e, utilização de um composto
BRPI0313647A2 (pt) composições de inalação